Abbonarsi

Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography - 29/06/13

Doi : 10.1016/j.ahj.2013.04.001 
Juan Luis Gutiérrez-Chico, MD, PhD, FESC, FACC a, Lorenz Räber, MD b, Evelyn Regar, MD, PhD, FESC a, Takayuki Okamura, MD, PhD a, Carlo di Mario, MD, PhD, FESC, FACC c, Gerrit-Anne van Es, MSc, PhD d, Stephan Windecker, MD, PhD, FESC b, Patrick W. Serruys, MD, PhD, FESC, FACC a,
a Erasmus Medical Centre, Thoraxcentre, Rotterdam, The Netherlands 
b Schweizerisches Herzzentrum, Inselspital, Bern, Switzerland 
c Cardiovascular Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, London, United Kingdom 
d Cardialysis BV, Rotterdam, The Netherlands 

Reprint requests: Patrick W. Serruys, MD, PhD, FESC, FACC, Erasmus MC, Thoraxcenter, Ba583a, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.

Riassunto

Background

Histologic experimental studies have reported incomplete neointimal healing in overlapping with respect to nonoverlapping segments in drug-eluting stents (DESs), but these observations have not been confirmed in human coronary arteries hitherto. On the contrary, angiographic and optical coherence tomography studies suggest that DES overlap elicits rather an exaggerated than an incomplete neointimal reaction.

Methods

Optical coherence tomography studies from 2 randomized trials including sirolimus-eluting, biolimus-eluting, everolimus-eluting, and zotarolimus-eluting stents were analyzed at 9- to 13-month follow-up. Coverage in overlapping segments was compared versus the corresponding nonoverlapping segments of the same stents, using statistical pooled analysis.

Results

Forty-two overlaps were found in 31 patients: 11 in sirolimus-eluting stents, 3 in biolimus-eluting stents, 17 in everolimus-eluting stents, and 11 in zotarolimus-eluting stents. The risk ratio of incomplete coverage was 2.35 (95% CI 1.86-2.98) in overlapping versus nonoverlapping segments. Thickness of coverage in overlaps was only 85% (95% CI 81%-90%) of the thickness in nonoverlaps. Significant heterogeneity of the effect was observed, especially pronounced in the comparison of thickness of coverage (I2 = 90.31).

Conclusions

The effect of overlapping DES on neointimal inhibition is markedly heterogeneous: on average, DES overlap is associated with more incomplete and thinner coverage, but in some cases, the overlap elicits an exaggerated neointimal reaction, thicker than in the corresponding nonoverlapping segments. These results might help to understand why overlapping DES is associated with worse clinical outcomes, both in terms of thrombotic phenomena and in terms of restenosis and revascularization.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Randomized controlled trial registration nos. NCT00389220 and NCT00617084NCT00389220NCT00617084.


© 2013  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 166 - N° 1

P. 83 - luglio 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • Heart failure performance measures: Eligibility and implementation in the community
  • Cecilia Berardi, Alanna M. Chamberlain, Francesca Bursi, Margaret M. Redfield, Sheila M. McNallan, Susan A. Weston, Ruoxiang Jiang, Véronique L. Roger
| Articolo seguente Articolo seguente
  • Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading
  • In-Suk Kim, Young-Hoon Jeong, Udaya S. Tantry, Yongwhi Park, Dong-Hyun Lee, Kevin P. Bliden, Jin-Sin Koh, Jeong Rang Park, Jae-Sik Jang, Seok-Jae Hwang, Eun-Ha Koh, Choong Hwan Kwak, Jin-Yong Hwang, Sunjoo Kim, Paul A. Gurbel

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.